FDA Approves Depemokimab for Severe Asthma: Once-Yearly Injection for Eosinophilic Phenotype

Executive Brief

News Report

The News: FDA approves depemokimab for severe asthma treatment.
Clinical Win: New once-yearly injection improves management of eosinophilic asthma.
Target Specialty: Pulmonology

Key Data at a Glance

Approval Date: December 16, 2025
Clinical Trials: SWIFT-1 and SWIFT-2
Patient Population: Aged 12 years and older with eosinophilic phenotype

The FDA announced the approval of depemokimab (Exdensur) on December 16, 2025, for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. This approval marks a significant advancement in the management of severe asthma, providing a new therapeutic option for patients who have not achieved adequate control with existing therapies.

Clinical Context

Severe asthma, particularly the eosinophilic phenotype, poses a significant burden on patients and healthcare systems due to its association with frequent exacerbations and poor quality of life. Patients with this phenotype typically experience ongoing symptoms despite treatment with high-dose inhaled corticosteroids and other controller medications. Current treatment options include biologics targeting specific pathways involved in the inflammatory process, but many patients remain inadequately controlled. The introduction of depemokimab offers a new mechanism of action, targeting interleukin-5 (IL-5), which plays a crucial role in eosinophil maturation and activation. By providing a once-every-six-month injection, depemokimab aims to improve adherence and overall asthma control, addressing a critical gap in the treatment landscape.

Key Findings

The FDA approved depemokimab (Exdensur) for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older [1].

The approval was based on data from two identical clinical trials, SWIFT-1 and SWIFT-2, which included a total of 762 patients with asthma not well controlled on their background medications [1].

Patients received either 100 mg of depemokimab or placebo via subcutaneous injection every six months for a duration of 52 weeks [1].
Clinicians should consult current prescribing information for full dosing guidance.

The primary endpoint was the annualized rate of asthma exacerbations requiring medical intervention, with results demonstrating a statistically significant reduction in exacerbation rates for those treated with depemokimab compared to placebo [1].

What This Means for Clinical Practice

Depemokimab is now available for patients meeting the criteria for severe asthma with an eosinophilic phenotype. The ability to administer this treatment once every six months may enhance patient adherence and reduce the frequency of exacerbations, ultimately improving patient quality of life. Clinicians should consider incorporating depemokimab into treatment plans for patients who have not responded adequately to standard therapies. Ongoing monitoring of patient outcomes will be essential to evaluate the long-term effectiveness and safety of this new treatment option in clinical practice.

In summary, the approval of depemokimab represents a promising addition to the therapeutic arsenal for managing severe asthma. As clinicians adopt this new treatment, questions remain regarding its long-term impact on patient outcomes and its role in combination with existing therapies.

Clinical Perspective

Workflow: Incorporating depemokimab into treatment plans may streamline management for patients with severe asthma.

Economics: The potential for reduced exacerbation rates could lead to decreased healthcare costs associated with emergency care.

Patient Outcomes: Improved adherence to treatment may enhance overall patient outcomes and quality of life.

Dr. Nikhil Chatterjee, Pulmonology

FDA Approves Depemokimab for Severe Asthma: Once-Yearly Injection for Eosinophilic Phenotype

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Related Articles

FDA Approves Depemokimab for Severe Asthma: Eosinophilic Phenotype Treatment

Severe Asthma Biologics: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2025

Verified HCP Portal